Evidence map›Paper›PMID 35115492›Full record

ArticleNature communications2022

TNF antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models.

Jiao Wu, Zhuan Feng, Liang Chen, Yong Li, Huijie Bian, Jiejie Geng, Zhao-Hui Zheng, Xianghui Fu, Zhuo Pei, Yifei Qin and 9 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
36.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 1 synthesis or guideline pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Jiao Wu *Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. jiaowubio@hotmail.com.ORCID http://orcid.org/0000-0002-9718-5499
Zhuan Feng *National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Liang Chen *School of Medicine, Shanghai University, Shanghai, China.
Yong Li *Xijing 986 Hospital Department, Fourth Military Medical University, Xi'an, China.
Huijie BianNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Jiejie GengNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Zhao-Hui ZhengDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Xianghui FuDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Zhuo PeiNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Yifei QinNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Liu YangNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Yilin ZhaoDepartment of Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Ke WangNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Ruo ChenNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Qian HeNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Gang NanNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China.
Xuejun JiangCell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. jiangx@mskcc.org.ORCID http://orcid.org/0000-0002-8670-3828
Zhi-Nan ChenNational Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, China. znchen@fmmu.edu.cn.ORCID http://orcid.org/0000-0001-5512-4623
Ping ZhuDepartment of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. zhuping@fmmu.edu.cn.ORCID http://orcid.org/0000-0002-8391-4945
Air Force Medical University · CNXijing Hospital · CNMemorial Sloan Kettering Cancer Center · USGuangdong Pharmaceutical University · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNShanghai University · CN

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Ferroptosis is a nonapoptotic cell death process that requires cellular iron and the accumulation of lipid peroxides. In progressive rheumatoid arthritis (RA), synovial fibroblasts proliferate abnormally in the presence of reactive oxygen species (ROS) and elevated lipid oxidation. Here we show, using a collagen-induced arthritis (CIA) mouse model, that imidazole ketone erastin (IKE), a ferroptosis inducer, decreases fibroblast numbers in the synovium. Data from single-cell RNA sequencing further identify two groups of fibroblasts that have distinct susceptibility to IKE-induced ferroptosis, with the ferroptosis-resistant fibroblasts associated with an increased TNF-related transcriptome. Mechanistically, TNF signaling promotes cystine uptake and biosynthesis of glutathione (GSH) to protect fibroblasts from ferroptosis. Lastly, low dose IKE together with etanercept, a TNF antagonist, induce ferroptosis in fibroblasts and attenuate arthritis progression in the CIA model. Our results thus imply that the combination of TNF inhibitors and ferroptosis inducers may serve as a potential candidate for RA therapy.

Indexed as

AnimalsArthritis, ExperimentalArthritis, RheumatoidCells, CulturedDisease Models, AnimalDrug Therapy, CombinationEtanerceptFerroptosisFibroblastsGlutathioneHumansImidazolesKetonesLipid PeroxidationMicePiperazinesEtanerceptGlutathioneimidazole ketone erastinImidazolesKetonesPiperazinesReactive Oxygen SpeciesTumor Necrosis Factor Inhibitors

Identifiers

PMID35115492
PMCPMC8813949
OpenAlexW4210367362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.